PUMA BIOTECHNOLOGY, INC. (PBYI) Operating margin 2017–2025
PUMA BIOTECHNOLOGY, INC. (PBYI) operating margin by fiscal year — reported operating income divided by reported revenue.
16.3%FY2025 · since FY2017: -1056.1% → 16.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 16.3% | +2.9 pp |
| FY2024 | 13.4% | -0.4 pp |
| FY2023 | 13.9% | +3.4 pp |
| FY2022 | 10.4% | +9.9 pp |
| FY2021 | 0.5% | +14.0 pp |
| FY2020 | -13.5% | +0.8 pp |
| FY2019 | -14.3% | +23.4 pp |
| FY2018 | -37.7% | +1018.4 pp |
| FY2017 | -1056.1% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More PBYI financial trends
PBYI RevenuePBYI Net incomePBYI Net marginPBYI Gross profitPBYI Gross marginPBYI Operating incomePBYI Operating cash flowPBYI Free cash flowPBYI Capital expendituresPBYI Return on equityPBYI Stock buybacksPBYI Dividends paidPBYI Total assetsPBYI Total liabilitiesPBYI Shareholders’ equityPBYI overview →